Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: An exploratory study
Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: An exploratory study
复制标题
DOI：
10.1097/01.chi.0000136563.31709.b0
复制
发表时间：
2004-10-01
影响因子：
13.3
通讯作者：
Brent, DA
中科院分区：
文献类型：
--
作者：
Campo, JV;Perel, J;Brent, DA
目的：评价西酞普兰治疗儿童功能性复发性腹痛及其合并内分泌障碍的潜在疗效、耐受性和安全性。方法：25例7~18岁复发性腹痛的临床转诊儿童和青少年，参加了一项为期12周、剂量灵活、开放标签的西酞普兰试验。主要的结果衡量标准是临床总体印象量表的改善，响应者的评分为1(非常大的改善)或2(非常大的改善)。二次测量包括自我和父母报告腹痛、焦虑、抑郁、其他躯体症状和功能障碍。使用标准化核对表评估副作用。数据采用意向处理格式进行分析，最后一次观察继续进行。结果：21名受试者(84%)被归类为应答者(临床总体印象量表改进52分)。西酞普兰总体耐受性良好。四名受试者提前退出，其中一名是由于报告的视觉副作用。在研究过程中，与基线相比，腹痛、焦虑、抑郁、其他躯体症状和功能障碍的评分都有显著改善。结论：西酞普兰是治疗儿童功能性复发性腹痛的一种有前景的治疗方法，值得通过随机、安慰剂对照的临床试验进一步研究。
Objective: To assess the potential efficacy, tolerability, and safety of citalopram in the treatment of functional pediatric recurrent abdominal pain and comorbid internalizing disorders. Method: Twenty-five clinically referred children and adolescents with recurrent abdominal pain aged 7 to 18 years, inclusive, participated in a 12-week, flexible-dose, open-label trial of citalopram. Primary outcome measure was the Clinical Global Impression Scale-Improvement, with responders defined by ratings of 1 (very much improved) or 2 (much improved). Secondary measures included self- and parent reports of abdominal pain, anxiety, depression, other somatic symptoms, and functional impairment. Side effects were assessed using a standardized checklist. Data were analyzed using an intent-to-treat format and the last observation carried forward procedure. Results: Twenty-one subjects (84%) were classified as responders (Clinical Global Impression Scaled improvement score 52). Citalopram was generally well tolerated. Four subjects withdrew prematurely, one due to reported visual side effects. Ratings of abdominal pain, anxiety, depression, other somatic symptoms, and functional impairment all improved significantly over the course of the study compared with baseline. Conclusions: Citalopram is a promising treatment for functional pediatric recurrent abdominal pain and deserves additional study with a randomized, placebo-controlled clinical trial.